文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛创伤与烧伤

创伤患者体外支持:TQIP数据库中急性呼吸窘迫综合征患者的分析

Extracorporeal support for trauma: A trauma quality improvement project (TQIP) analysis in patients with acute respiratory distress syndrome.
PubMed 文献 · Am J Emerg Med · 2021-04-30
一句话结论创伤合并ARDS患者使用ECMO可能改善生存,尤其年轻胸部损伤、ARDS早期启动者,但并发症与住院时间增加。

本研究基于创伤质量改进项目(TQIP)数据库2013至2016年数据,对创伤合并ARDS患者中接受ECMO者与倾向性匹配的常规管理队列进行比较分析。最终纳入3680例,其中97例(2.6%)接受ECMO。匹配后单因素分析显示ECMO组院内死亡率较低(23% vs 50%,p<0.001),但并发症发生率更高(p<0.005),住院时间更长。ECMO组中早期启动(<7天)与更短的住院时间、ICU停留时间和机械通气天数相关。抗凝与否在出血风险或死亡率上无差异。作者认为ECMO可能改善创伤ARDS患者生存,尤其年轻胸部损伤、ARDS早期患者,但以并发症增加和住院时间延长为代价。

要点

  • 创伤合并ARDS接受ECMO者匹配后院内死亡率23% vs 常规管理50%(p<0.001),但并发症更多(p<0.005)、住院时间更长。
  • ECMO组中早期启动(<7天)与更短住院时间、ICU停留时间和更少机械通气天数相关。
  • ECMO期间抗凝未增加出血风险或死亡率,即使存在颅脑损伤。
  • 作者认为ECMO可能改善创伤ARDS患者生存,尤其年轻胸部损伤、ARDS早期患者。
  • ECMO的生存获益伴随并发症发生率和住院时间增加的代价。

适用人群与场景

  • TQIP数据库2013至2016年收录的创伤合并ARDS患者,最终分析3680例,其中97例(2.6%)接受ECMO。

研究设计与关键结果

  • 研究类型为基于TQIP数据库的倾向性匹配比较分析,纳入3680例创伤合并ARDS患者,97例(2.6%)接受ECMO。
  • 倾向性评分匹配变量包括年龄、性别、入院生命体征(HR、SBP)和GCS、损伤严重度评分(ISS)及多个体区的简明损伤定级(AIS)评分。
  • 匹配后单因素分析:ECMO组院内死亡率23% vs 非ECMO组50%(p<0.001),ECMO组并发症发生率更高(p<0.005),住院时间更长。
  • ECMO组中早期启动(<7天)与更短住院时间、ICU停留时间和更少机械通气天数相关。
  • 两组间抗凝状态无差异。
  • ECMO期间抗凝未增加出血风险或死亡率,即使存在颅脑损伤。

证据类型、等级与局限

  • 证据类型:基于创伤质量改进项目(TQIP)数据库的倾向性匹配比较分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ECMO用于创伤合并ARDS可能改善生存,尤其年轻胸部损伤、ARDS早期患者。
  • 作者指出,ECMO的生存获益以并发症发生率可能增加和住院时间延长为代价。
  • 作者指出,ECMO期间抗凝未增加出血风险或死亡率,即使存在颅脑损伤。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The use of extracorporeal membrane oxygenation (ECMO) in trauma patients with severe acute respiratory distress syndrome (ARDS) continues to evolve. The objective of this study was to perform a comparative analysis of trauma patients with ARDS who received ECMO to a propensity matched cohort of patients who underwent conventional management.

METHODS: The Trauma Quality Improvement Program (TQIP) database was queried from 2013 to 2016 for all patients with ARDS and those who received ECMO. Demographics, as well as clinical, injury, intervention, and outcome data were collected and analyzed. Patients with ARDS were divided into two groups, those who received ECMO and those who did not. A propensity score analysis was performed using the following criteria: age, gender, vital signs (HR, SBP) and GCS on admission, Injury Severity Score (ISS), and Abbreviated Injury Scale (AIS) score in several body regions. Outcomes between the groups were subsequently compared using univariate as well as Cox regression analyses. Secondary outcomes such as hospitalization (HLOS), ICU length-of-stay (LOS) and ventilation days stratified for patient demographics, timing of ECMO and anticoagulation status were compared.

RESULTS: Over the 3-year study period, 8990 patients with ARDS were identified from the TQIP registry. Following exclusion, 3680 were included in the final analysis, of which 97 (2.6%) received ECMO. On univariate analysis following matching, patients who underwent ECMO had lower overall hospital mortality (23 vs 50%, p < 0.001) with higher rates of complications (p < 0.005), including longer HLOS. In those undergoing ECMO, early initiation (<7 days) was associated with shorter HLOS, ICU LOS, and fewer ventilator days. No difference was observed between the two groups with regard to anticoagulation.

CONCLUSION: Extracorporeal membrane oxygenation use in trauma patients with ARDS may be associated with improved survival, especially for young patients with thoracic injuries, early in the course of ARDS. Anticoagulation while on circuit was not associated with increased risk of hemorrhage or mortality, even in the setting of head injuries. The mortality benefit suggested with ECMO comes at the expense of a potential increase in complication rate and prolonged hospitalization.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Henry R, Ghafil C, Piccinini A, et al. Extracorporeal support for trauma: A trauma quality improvement project (TQIP) analysis in patients with acute respiratory distress syndrome. Am J Emerg Med. 2021. PMID: 33962131. doi:10.1016/j.ajem.2021.04.083

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。